2026-11-10 · 2026-11 / week-2

HIMS’s guide reset is real; the Lilly channel leaves no bounded short

HIMS’s guide reset is real; the Lilly channel leaves no bounded short

Screen result: Reject / no trade. Hims & Hers cut its 2026 Adjusted EBITDA midpoint by 11% as Q3 gross margin fell to 57%. That is real operating pressure. Yet revenue grew 49%, nine-month free cash flow stayed positive, Lilly added a branded-drug channel days before results, and the latest reported short position was already crowded. From the $22.16 after-hours reference, the base case is flat and an observed-price squeeze stress is +29.3%. The short fails 10/5.

Run scope: U.S. market, short opportunities only.

Publication time: November 10, 2026, 13:00 SGT.

Quote cutoff: HIMS after-hours reference at 19:59 EST on November 9; all prices are research references, not entries.

Opportunity Ranking

Rank Candidate Direction Mispricing Evidence Freshness Catalyst Window Positioning 10/5 Status Tradeability Main Rejection Risk
1 Hims & Hers (HIMS) Short screen Q3 margin and FY EBITDA reset against 49% revenue growth, a new Lilly channel, and a 1.81x Desk-calculated trailing-sales multiple Nov. 9 Q3 release and 10-Q; Nov. 6 Lilly agreement First post-result regular session Nov. 10; next post-event short-interest settlement Nov. 13, scheduled release Nov. 24 53.47M shares short, 25.24% of the provider’s float, as of Oct. 15; stale Reject: 0% base decline, +29.3% adverse stress, -5.7% weighted gross short return Liquid listed common stock, but current spread, locate, borrow and exit capacity are unverified Strong growth and branded-drug access can squeeze a crowded short
2 Archer Aviation (ACHR) Short screen Heavy operating losses against a newly granted FAA Market Survey certificate and an imminent Boeing transaction close Nov. 9 Q3 release and 10-Q First post-result regular session Nov. 10; LA survey operations expected in coming weeks Current short and borrow data not verified Reject: certification, transaction and funding paths leave upside unbounded After-hours mark is not a regular-session entry FAA approval and Boeing assets could accelerate the commercial narrative
3 AST SpaceMobile (ASTS) Short screen Long execution path and heavy cash needs against a $1B Japan funding agreement, DPAS priority and launch plans Nov. 9 Q3 release and 10-Q First post-result regular session Nov. 10; intermittent U.S. service targeted before year-end Current short and borrow data not verified Reject: fresh government and funding catalysts weaken the short case After-hours sources conflict; no entry-quality evidence Funding, launch cadence or service milestones could drive another repricing
4 SPDR S&P 500 ETF (SPY) Broad-market control No issuer-specific disagreement; Nov. 9 close rose 2.37% Nov. 9 close No single company catalyst Not used as a positioning thesis No standalone short Broad and liquid, but no short thesis identified A market-wide move can overwhelm an issuer-only screen

HIMS ranks first for information value, not as the best executable short. Its Q3 filing, revised guidance and new Lilly access agreement create a clear test of whether sales growth can convert into durable margins. ACHR and ASTS have stronger near-term upside catalysts and weaker valuation anchors, so their adverse cases cannot be responsibly bounded. SPY is the broad-market control.

Candidate price sources show why extended-hours marks are not interchangeable. HIMS closed at $22.94 and was $22.16 at 19:59 EST. ACHR was $4.56 at 19:59, while ChartExchange showed $4.54 at 16:59. ASTS was $36.62 at 19:59, while ChartExchange showed $38.40 at 16:59. Those ASTS observations are not averaged. StockAnalysis and ChartExchange also differ slightly on the ASTS regular close, $36.89 versus $36.91. These are reference data, not execution evidence.

Selected screen: HIMS.

Why this one now: The fresh result gives a concrete margin and cash-conversion test, while the Nov. 6 Lilly agreement creates a new countercase that the Q3 numbers cannot yet measure.

What should surprise the reader: The company’s weakest Q3 unit-economics evidence arrived after a new branded-drug distribution path was announced. The market has no reported conversion or margin data for that channel yet.

Why This Is the Highest-Information Screen

This is a new evidence boundary, not a refreshed version of the August HIMS note. That note was based on Q2 results and asked whether Q3 revenue, gross margin and cash flow would stabilize. Q3 revenue of $890.4M and Adjusted EBITDA of $82.4M landed inside the prior company ranges, but gross margin fell from Q2’s 64% to 57%. Nine-month Free Cash Flow was $10.8M versus $60.0M a year earlier. The August note’s $34 base-price marker was not reached: HIMS closed at $22.94 on Nov. 9 and showed $22.16 after hours.

That is a forecast miss at the first Q3 checkpoint, not a realized trading return. The August note also projected a $32 probability-weighted price from a $28.77 reference; the current after-hours mark is 23.0% below that reference. The result supports the margin-risk concern but does not prove a short is attractive now. The quote has already fallen, while the new Lilly agreement changes the next operating test.

The current screen draws on three mechanisms: HIMS margin and cash conversion versus branded-GLP-1 access; ACHR certification and acquisition catalysts versus cash burn; and ASTS launch commitments and government funding versus deployment risk. These are materially different businesses and catalysts. None clears the short hurdle.

Why This Can Move More Than 5% Soon

The first regular U.S. session after HIMS reported is Nov. 10. The latest verified extended-hours reference is $22.16, down $0.78, or 3.40%, from the Nov. 9 regular close. The regular session had already closed at $22.94 before the company’s 5:00 p.m. earnings call. Do not attribute the full Nov. 9 regular-session loss to the Q3 release.

The result can still move the stock materially: FY26 Adjusted EBITDA guidance fell, but Q3 revenue grew 49% and the company introduced access to Lilly medicines through its platform on Nov. 6. A market response above $28 is possible if investors prioritize growth and the new channel, while a lower sales multiple could move the stock toward $19. Neither path is bounded by live borrow or order-book evidence.

10/5 Asymmetry Gate

From the $22.16 after-hours reference, the highest-probability case is flat. The modeled short gain in the top case is 15.5%, but the credible observed-price squeeze stress is a 29.3% rise. Gross reward to adverse risk is 0.53:1. The weighted price-only short return is -5.7% before borrow, spread, slippage or fees.

The short therefore fails three gates: base decline is below 10%, adverse upside exceeds 5%, and gross reward-to-risk is below 2:1. Missing live execution data compounds the failure; it does not cause it.

What Should Surprise the Reader

Lilly and Hims & Hers announced access to Zepbound and Foundayo through the Hims platform on Nov. 6. Eligible patients can receive a prescription from a Hims provider and obtain the medicines at Lilly’s self-pay prices without leaving the platform. The announced prices start at $149 per month for Foundayo and $299 for Zepbound. Lilly and Hims also said Hims had never offered compounded copies of Lilly’s drugs and would not do so.

That is a distribution agreement, not evidence of patient conversion, retention, gross profit or cash received. The Q3 period ended Sept. 30, so it contains no performance from this agreement. The first useful test is whether Hims can add branded-drug revenue without a further decline in margin or cash conversion.

The Setup

Filed facts. Q3 revenue was $890.4M, up 49% year over year, and subscribers rose 13% to 2.788M. U.S. revenue grew 21%; Rest-of-World revenue grew 321%, with the company attributing growth partly to the Eucalyptus acquisition. Gross margin was 57%, down from 74% a year earlier and 64% in Q2. Net loss was $33.0M. Adjusted EBITDA increased to $82.4M from $78.4M, but the company reduced full-year guidance.

Cash bridge. Q3 operating cash flow was $65.4M and company-defined Free Cash Flow was $26.0M, both below the prior-year quarter’s $148.7M and $79.4M. Nine-month Free Cash Flow was $10.8M versus $60.0M. Positive Q3 cash flow is meaningful counterevidence to a near-term funding thesis; the deterioration over nine months supports scrutiny of unit economics. Adjusted EBITDA is not cash flow.

Issuer explanation. The 10-Q attributes higher cost of revenue to weight-loss offerings, some with higher product, packaging and shipping costs, shorter shipping cadences, more subscribers, international growth and acquisitions. Cost of revenue rose 143% to $381.2M, faster than revenue. These disclosures explain the pressure; they do not establish that it will persist.

Guide bridge. August’s FY26 revenue midpoint was $3.20B and Adjusted EBITDA midpoint was $300M. The Nov. 9 midpoint is $3.14B and $267M, respectively: a 1.9% revenue reduction and an 11.0% Adjusted EBITDA reduction. Q4 guidance is $875M–$895M revenue and $70M–$90M Adjusted EBITDA, or an 8%–10% margin. The company revised its Adjusted EBITDA definition in Q3 to include net foreign-exchange gains and losses; it says those amounts were not significant in earlier periods and did not recast them.

The Market Price

StockAnalysis reports a Nov. 9 regular close of $22.94, down 11.77%, and an after-hours mark of $22.16 at 19:59 EST, down 3.40% from the close. StockAnalysis reports regular-session volume of 50.12M; ChartExchange reports 45.26M. The price rows agree, but the volume figures do not, so volume is not used as positioning evidence. Neither source provides the live spread, depth, venue mix or exit capacity required for a short entry.

The valuation check uses the after-hours reference and latest filed actual common shares:

  • Nov. 6 outstanding Class A shares: 226.035M.
  • Nov. 6 outstanding Class V shares: 8.378M. The 10-Q says the two classes have identical liquidation and dividend rights; Class V has extra voting rights.
  • Total reported common shares: 234.412M.
  • Market capitalization proxy: $22.16 × 234.412M = $5.195B.
  • TTM revenue: FY2025 $2.348B + nine-month 2026 $2.252B − nine-month 2025 $1.730B = $2.870B.
  • Desk-calculated market-cap-to-TTM-sales ratio: 1.81x.

This is a basic-share price-to-sales measure, not enterprise value or a diluted valuation. At Sept. 30, Hims reported $712.2M of cash and available-for-sale investments and $1.4025B of convertible-note principal. Lease and acquisition claims are not included in the price-to-sales calculation.

TGMCharts estimates a five-year HIMS price-to-sales range of 1.53x to 13.01x and a 3.78x average. Its displayed current ratio uses a Nov. 9 market cap and revenue only through June 30, before Q3. I do not use its stale current ratio. The reported historical low is only a rough downside stress anchor, not a fair-value estimate.

The Mispricing

The short case is that scale is not translating into gross profit or Adjusted EBITDA as quickly as the earlier revenue story implied. The fresh guide cut makes that disagreement measurable. The countercase is that Q3 revenue, subscribers and U.S. revenue all grew, Q3 Free Cash Flow remained positive, and the Lilly agreement may replace some compounding exposure with branded access.

At $22.16, the updated basic-share price-to-sales ratio is about 1.81x. That is not an obvious overvaluation against the provider’s own estimated historical range. Nor does a low multiple prove undervaluation: the business carries convertible claims, product-mix risk, regulatory exposure and acquisition complexity. No reliable consensus model in this run establishes what earnings or margin trajectory the market currently discounts.

The market may be right that margin pressure is structural. It may also be right to value the new channel before patient conversion appears in reported results. We do not have enough evidence to distinguish those outcomes with a favorable short payoff.

The Positioning

ChartExchange’s FINRA-sourced table shows 53,473,095 HIMS shares short at the Oct. 15 settlement, 25.24% of its displayed 211.88M float, with 5.01 days to cover. The share count and float denominator are provider fields, not a current borrow quote. FINRA describes short interest as a twice-monthly snapshot; it is not daily short-sale volume.

The NYSE calendar schedules the Oct. 30 settlement report for Nov. 10. At this run’s cutoff, ChartExchange’s displayed official series still showed Oct. 15 as the latest observation; the new report may arrive later today. That settlement predates the Q3 release. The first scheduled post-result settlement is Nov. 13, with publication Nov. 24. Current positioning, locate availability, borrow cost, recall terms, options exposure and dealer flows remain unknown. The Oct. 15 figure is a squeeze warning, not proof of current crowding.

The Catalyst

Catalyst Timing What would confirm the short thesis What would weaken it
First regular-session response to Q3 Nov. 10, 2026 Regular-session acceptance below the after-hours reference alongside no positive new operating disclosure; this is a price test, not standalone proof A strong rebound or broad-market move; neither alone proves the operating thesis
Lilly channel rollout Announced Nov. 6; conversion timing not disclosed Later filings show added revenue without improved margin or repeat engagement Meaningful patient conversion with stable or rising gross margin
Oct. 30 short-interest publication Scheduled Nov. 10; settlement predates Q3 Record raw shares and settlement date; it cannot show post-event positioning A low reading may reduce the squeeze concern, but does not prove borrow availability
Nov. 13 short-interest settlement Scheduled publication Nov. 24 Compare raw shares with Oct. 15 and Oct. 30, while keeping the lag explicit Material covering could remove fuel from a short thesis
Q4/FY2026 results Exact release date not verified Compare revenue and Adjusted EBITDA with the $875M–$895M and $70M–$90M Q4 ranges; reconcile gross margin, FCF and Lilly/Novo mix Better margin conversion or a raised outlook would challenge the short case

The cheapest falsification sequence is the Nov. 10 regular-session response, followed by the next filing’s product-mix, gross-margin and cash-flow tables. A quote below the after-hours reference alone is not fundamental confirmation.

The Payoff

The map is a one-session, reference-only stress test from the $22.16 after-hours mark. It does not assume an executable short or treat a target as a price cap.

  • Top case: price falls to $18.73 if the market reprices HIMS to the provider-estimated 1.53x historical low applied to the refreshed TTM sales per reported common share. This is a weakly supported sensitivity, not fair value.
  • Base case: price remains at $22.16 as the lower guide is balanced by 49% sales growth and the new Lilly channel. This is the highest-probability judgment, not an observed frequency.
  • Bottom case: price returns to $28.66, the Nov. 4 intraday high, if investors favor branded-drug access and growth and short covering accelerates. This observed level is a stress, not a maximum squeeze price.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff from $22.16 Horizon Conditions Evidence Quality
Top Case 20% $18.73 +15.5% short gross return Nov. 10 regular-session close Guide reset dominates; the stock retests the provider-estimated historical P/S low on refreshed TTM sales Low
Base Case 50% $22.16 0.0% Nov. 10 regular-session close Growth, positive Q3 FCF and the Lilly channel offset the lower guide Low
Bottom Case 30% $28.66 -29.3% short gross return Nov. 10 regular-session close Short covering and a growth-led rebound return the price to its Nov. 4 intraday high Medium-low
Invalidation n/a Insufficient data for a price-only invalidation level Re-underwrite if Q4 margin and cash conversion stabilize or the Lilly channel produces material repeat revenue Next reported quarter Evidence of improved branded mix or stronger guidance removes the core margin-reset premise Medium

Probability-weighted expected price: $23.42, using 20% × $18.73 + 50% × $22.16 + 30% × $28.66.

Probability-weighted gross short return: -5.7% before borrow, spread, slippage, funding and fees.

Current market level and timestamp: $22.16, after-hours observation at 19:59 EST Nov. 9, 2026.

Primary instrument: HIMS common stock, NYSE.

10/5 favorable base move: 0.0% decline.

10/5 credible adverse move: 29.3% rise to the observed Nov. 4 high; larger losses remain possible.

10/5 measurement basis: reference-only after-hours price.

10/5 status: Reject.

Confidence: Low. The short-interest figure is stale; the historical-multiple anchor is approximate; scenario weights are judgments, not observed frequencies.

The model excludes all trading and borrow costs because current terms were not verified. Those costs cannot rescue an already negative gross expected return.

The Kill Shot

The strongest counterargument is that the market has already compressed HIMS’s multiple while revenue and subscribers continue to grow. The company reported positive Q3 Free Cash Flow, and Lilly’s agreement adds access to two branded medicines on the platform. If that channel converts customers and stabilizes margin, the Q3 guide reset may mark a transition cost rather than a lasting earnings ceiling.

The most fragile short assumption is that lower gross margin persists after the branded channel scales. The Q3 period ended before Lilly’s Nov. 6 agreement, so the next reported quarter is the first direct test. A one-session downside move cannot settle that question.

What Could Go Wrong

A short can lose more than the $28.66 stress through a larger squeeze, a stronger Q4 guide, better branded-drug conversion, a market-wide rally or favorable healthcare news. Borrow may become expensive or unavailable; a lender can recall shares; a gap or halt can defeat a planned exit. After-hours spreads and depth are not verified. A thin or fast market can make realized losses exceed a modeled scenario.

The $1.4025B note principal, acquisition claims, evolving healthcare rules, product costs and share-based compensation also matter. These are risks to the operating thesis, not a mechanically protective floor for a short.

What Would Prove This Wrong

The short screen should be retired if subsequent filings show that Lilly and Novo access lift repeat prescriptions while gross margin stabilizes or improves; Q4 Adjusted EBITDA meets guidance without further margin erosion; or Free Cash Flow recovers while the basic share count remains controlled. These are operating tests. A single price move or the stale Oct. 15 short-interest count is not enough.

Risk Audit

Risk Evidence and consequence
Operating upside Q3 sales rose 49%; U.S. sales rose 21%; subscribers rose 13%. These are current facts and support the long case.
Product mix and margin Gross margin fell 7 percentage points sequentially; cost of revenue grew 143% year over year. The duration of the mix effect is unknown.
Lilly agreement Announced access and self-pay pricing are facts; customer uptake, unit economics and retention are not yet reported.
Crowding Oct. 15 short interest was 25.24% of the provider’s float; the count is stale and the denominator is provider-defined.
Financing and dilution Sept. 30 liquidity and convertible principal are disclosed; future conversion, acquisition obligations and share issuance can change per-share value.
Execution Current spread, depth, venue quality, locate, borrow, recall terms and exit capacity are unverified.
Gap and event risk The scenario map is not a cap. Earnings, regulatory, product or policy news can gap through any reference level.

Best Trade Strategy

Decision: No trade. This screen does not support a short position.

Direction / instrument considered: Short HIMS common stock only; no options or leverage.

Entry: None. Keep entry.price null. The $22.16 after-hours mark is reference context only.

Execution: Blocked. A later screen would require a fresh regular-session quote, acceptable spread and depth, venue and volume quality, exit capacity, and verified locate, borrow cost and recall terms. It would also need a positive after-cost expected value and a base decline of at least 10% with credible upside risk no greater than 5%.

Do not trade: Do not use this screen as an order instruction. Do not short without locate and borrow terms. Do not use market orders, options, leverage, margin or price-floor logic.

Sources

Source Use
Hims & Hers Q3 2026 results, Nov. 9 Revenue, margin, loss, cash flow, Q4 and FY guidance, EBITDA definition
Hims & Hers Q3 2026 Form 10-Q Cost-of-revenue explanation, cash and investments, convertible notes, share classes, shares outstanding
Hims & Hers Q2 2026 results Prior FY26 revenue and Adjusted EBITDA guidance
Hims & Hers 2025 Form 10-K FY2025 revenue
Lilly and Hims & Hers agreement, Nov. 6 Announced branded-drug access, self-pay prices and clinical commitments
HIMS historical and after-hours prices, StockAnalysis Nov. 9 close, after-hours mark, OHLC and volume
HIMS Nov. 9 historical prices, ChartExchange Close and volume cross-check
HIMS short-interest table, ChartExchange Oct. 15 reported short position, provider float and days to cover
NYSE Group 2026 short-interest calendar Settlement and publication dates
FINRA, “Short Interest: What It Is, What It Is Not” Distinction between short interest and daily short-sale volume
HIMS price-to-sales history, TGMCharts Estimated five-year range; displayed current ratio uses revenue through June 30
ACHR Q3 2026 results, Nov. 9 Candidate financial, FAA and Boeing transaction evidence
Archer Aviation Q3 2026 Form 10-Q Candidate cash, operating loss and transaction context
ACHR historical and after-hours prices, StockAnalysis Nov. 9 regular close and 19:59 after-hours mark
ACHR earlier after-hours snapshot, ChartExchange Earlier 16:59 after-hours observation
AST SpaceMobile Q3 2026 results, Nov. 9 Candidate revenue, funding, DPAS and launch plan
AST SpaceMobile Q3 2026 Form 10-Q Candidate financial and cash-flow evidence
ASTS historical and after-hours prices, StockAnalysis Nov. 9 regular close and 19:59 after-hours mark
ASTS earlier after-hours snapshot, ChartExchange Earlier 16:59 after-hours observation
SPY Nov. 9 historical prices, ChartExchange Broad-market control

Research Quality Scorecard

Criterion Score Reason
Market disagreement 4/5 Fresh guide reset conflicts with high growth and a new branded channel
Evidence base 5/5 SEC filings, issuer releases and dated market observations
Positioning and flows 3/5 Reported short interest is stale; current borrow, options and flows are missing
Catalyst path 4/5 First post-result session and scheduled short-interest publications are observable; next result date is unknown
Payoff architecture 2/5 Reference-only map has flat base, negative weighted return and a 0.53:1 gross ratio
Invalidation discipline 4/5 Margin, repeat prescriptions, Q4 guidance and cash conversion are monitorable
Differentiated insight 4/5 Lilly access is new and untested in reported results; Q3 cannot resolve it
Client value 5/5 Prevents a short based on a margin story whose downside is not bounded
Total 31/40 Reject remains required because the 10/5 gates fail.

Bottom Line

Q3 confirms a real margin problem but does not create a short with favorable asymmetry. The stock’s 1.81x refreshed trailing-sales multiple is not a clear overvaluation signal; a newly announced Lilly channel, strong revenue growth and stale high short interest leave a credible squeeze path. The reference-only model has no base decline and a negative weighted gross return. Reject / no trade.

AI Illustration Prompt: Create a restrained editorial illustration about Hims & Hers at a margin and distribution crossroads. On a dark institutional desk, place two ledgers: one marked “Q3 revenue +49% / gross margin 57% / FY EBITDA midpoint -11%” and another marked “Lilly access announced Nov. 6 / uptake not yet reported.” Between them, show a narrow bridge from a telehealth interface toward two sealed, clearly labeled FDA-approved medicine cartons, with no patient imagery. In the background, place a faint share tape at “HIMS 22.16 after hours” and an unlabeled rising and falling price path with no arrow of certainty. Use graphite, midnight blue, clinical white and one muted amber accent. Forensic, quiet, premium financial-editorial style. No rockets, pill clichés, dollar-sign wallpaper or hype. Add a subtle readable “The Mispricing Desk” watermark.